Searching the RRID Resource Information Network
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
SciCrunch Registry is a curated repository of scientific resources, with a focus on biomedical resources, including tools, databases, and core facilities - visit SciCrunch to register your resource.
http://ims.cochrane.org/revman/about-revman-5
THIS RESOURCE IS NO LONGER IN SERVICE. Documented on January 5, 2023.A software package that does meta-analysis and provides results in tabular format and graphically., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025.
Proper citation: RevMan (RRID:SCR_003581) Copy
An Antibody supplier
Proper citation: Torrey Pines Biolabs (RRID:SCR_003580) Copy
A not-for-profit research and development laboratory focused on the design, development, and deployment of advanced technological solutions for the nation's most challenging and important problems in security, space exploration, healthcare, and energy. Their expertise includes the areas of guidance, navigation, and control systems; fault-tolerant computing; advanced algorithms and software solutions; modeling and simulation; and MEMS and multichip module technology. With a strong commitment to delivering working solutions to their sponsors, they apply their expertise to a variety of domains, including autonomous air, land, sea, and space systems; information integration; distributed sensors and networks; precision-guided munitions; and biomedical engineering; chemical/biological defense; and energy system modeling and management. When appropriate for the needs of their sponsors, they will work with commercial partners to transition their technology to commercial production.
Proper citation: Charles Stark Draper Laboratory (RRID:SCR_003736) Copy
A nonprofit devoted to spreading ideas, usually in the form of short, powerful talks (18 minutes or less). TED began as a conference where Technology, Entertainment and Design converged, and today covers almost all topics - from science to business to global issues - in more than 100 languages. Meanwhile, independently run TEDx events help share ideas in communities around the world.
Proper citation: TED (RRID:SCR_003739) Copy
A dropbox like model cloud-based, commercial data management and collaboration system designed specifically for research scientists. It helps manage and annotate data, track provenance and share this with colleagues.
Proper citation: Ovation (RRID:SCR_003737) Copy
An international consortium to develop and assess novel approaches to identify and characterize biological markers for colon cancer that will deepen the understanding of the variable make-up of tumors and how this affects the way patients respond to treatment. They will use cutting edge laboratory-based genome sequencing techniques coupled to novel computer modelling approaches to study both the biological heterogeneity of colon cancers (i.e. patient to patient variability) as well as tumor variation within the patient for example, by comparing primary tumors with metastases. This five year project brings together top scientists from European academic institutions offering a wide range of expertise, and partners them with pharmaceutical companies. The project is based on the premise that this genetic and epigenetic information, combined with a description of the molecular pathology of the tumor, will allow OncoTrack to generate a more accurate in-silico model of the cancer cell. This will facilitate the identification of predictive markers that can be used to guide the optimal therapy strategy at the level of the individual patient - and will also provide on-going prognostic guidance for the clinician. This project will not only advance understanding of the fundamental biology of colon cancers but will provide the means and approach for the identification of previously undetected biomarkers not only in the cancer under study, but potentially also in other solid cancers and, in doing so, open the door for personalized management of the oncology patient.
Proper citation: OncoTrack (RRID:SCR_003767) Copy
Consortium to accelerate the search for new, more effective combinations of treatments to tackle Tuberculosis and address pre-clinical research barriers to the discovery and development of new TB drug combinations. To overcome the challenges in Tuberculosis drug development they will create tools to accelerate PK-PD (Pharmacokinetic / Pharmacodynamic) analysis that are connected to clinical outcomes. By addressing the gaps in preclinical information, the consortium aims to provide a framework and tools to facilitate the transition of the best combinations of drugs to late phase development. They aim to develop an integrated set of laboratory-based models that will provide much-needed data to indicate the most appropriate doses and combinations of drugs for patients. In addition, the project will generate a comprehensive database of patient data from previous and on-going clinical trials for use as a reference for evaluating the performance of combination anti-TB drug regimens in these newly developed laboratory models. Ultimately, they aim to enable researchers to be able to use the information generated by the novel models to design better clinical trials involving TB patients. The aims of the consortium: * To systematically evaluate two successive panels of representative anti-tuberculosis drugs (licensed and novel) using a suite of standard, novel and enhanced preclinical model systems, with respect to performance in clinical trials * To refine the set of preclinical systems on the basis of these results in order to identify and define the currently optimal critical path in discovery and pre-clinical development for tuberculosis. * To develop an integrated PK-PD / Disease modelling and simulation framework for tuberculosis which will facilitate prediction of optimal combinations and design of clinical studies.
Proper citation: Predict-TB (RRID:SCR_003766) Copy
Videos and podcasts presenting the latest innovative research being conducted by the Stein Institute for Research on Aging medical faculty, with the aim of promoting healthy aging. Additionally, many of the public lectures from the Public Lecture Series are also available on UCSD-TV's website video on demand programming. The Lecture series allows affiliated faculty members of the Stein Institute for Research on Aging and other scientists from the UCSD School of Medicine, as well as individuals from surrounding academic and research institutions, to present the latest findings in their respective fields of expertise and share their present work with the general community. All of these lectures focus on topics related to healthy aging or age-related diseases.
Proper citation: Stein Institute for Research on Aging Video Archive (RRID:SCR_003761) Copy
Research informatics and analytics platform for the IMI OncoTrack consortium.
Proper citation: eTRIKS (RRID:SCR_003765) Copy
http://www.psidev.info/index.php?q=node/257
Markup language for encoding raw spectrometer output. From 2005-2008 there has existed two separate XML formats for encoding raw spectrometer output: mzData developed by the PSI and mzXML developed at the Seattle Proteome Center at the Institute for Systems Biology. It was recognized that the existence of two separate formats for essentially the same thing generated confusion and required extra programming effort. Therefore the PSI, with full participation by ISB, has developed a new format by taking the best aspects of each of the precursor formats to form a single one. It is intended to replace the previous two formats. This new format was originally given a working name of dataXML. The final name is mzML.
Proper citation: mzML (RRID:SCR_003763) Copy
A not-for-profit organization that initiates and manages drug development consortia that involve the pharmaceutical industry, academia, and the Dutch Government. The aim of all their consortia is to conduct pre-competitive research while strengthening the Netherlands' international reputation for drug development. The consortia are focused on addressing therapeutic areas that are listed as priority areas by the World Health Organization including: autoimmune diseases, cardiovascular diseases, cancer, infectious diseases, and diseases of the brain. The consortia are also focused on enabling: therapeutic target discovery, validation, and animal models; lead selection and in-silico modeling; predictive drug disposition and toxicology; biomarkers and biosensors; drug formulation, delivery, and targeting; and, production technologies. TI Pharma consortia aim to improve the efficiency of the drug-development process, with a focus on advancing regulatory science. In addition to research, TI Pharma also has objectives to train and educate scientists in the Netherlands on the drug discovery and development processes, as well as on entrepreneurship. Participants include: all Dutch universities and academic medical centers, more than 30 industrial partners, small-to-medium sized companies, and representatives from the Dutch Medicines Evaluation Board (Netherlands regulatory body for drugs).
Proper citation: TI Pharma (RRID:SCR_003758) Copy
http://bioinformatics.bc.edu/marthlab/wiki/index.php/PyroBayes
THIS RESOURCE IS NO LONGER IN SERVICE. Documented on January 6, 2023. A base caller for pyrosequences from the 454 Life Sciences sequencing machines.
Proper citation: PyroBayes (RRID:SCR_003757) Copy
Commercial organization developing a disruptive, proprietary technology platform for the direct, electronic analysis of single molecules. The instruments GridION and MinION are adaptable for the analysis of DNA, RNA, proteins, small molecules and other types of molecule. Consequently, the platform has a broad range of potential applications, including scientific research, personalized medicine, crop science and security / defence.
Proper citation: Oxford Nanopore Technologies (RRID:SCR_003756) Copy
Portal dedicated to the development and application of the latest advances in biomedical and behavioral science knowledge to issues of successful, healthy aging and the prevention and reduction of the burden of disability and disease in late life. Additionally, they provide numerous grants to junior faculty, as well as education programs for doctors and researchers through monthly Grand Rounds. From studying memory to identifying genes with important roles in aging, Stein Institute scientists are continuously pushing the boundaries of knowledge. One of their most promising ongoing projects is the Successful AGing Evaluation (SAGE) Study. SAGE is the only large-scale study on successful aging that considers the impact of positive psychological traits, such as resilience and wisdom, in addition to biological factors, providing a much more complete picture of older adults. Their monthly public lectures presented by renowned physicians and scientists are broadcast on UCSD-TV and have been viewed more than one billion times. This year they partnered with the Clinical and Translational Research Institute and the Osher Lifelong Learning Institute to organize Making Sense of Science, a course for older adults interested in science and health. In addition, They distribute a free monthly newsletter and work extensively with the community, participating in numerous events and conferences.
Proper citation: Stein Institute for Research on Aging (RRID:SCR_003759) Copy
http://neuroscienceblueprint.nih.gov/
Collaborative framework that includes the NIH Office of the Director and the 14 NIH Institutes and Centers that support research on the nervous system. By pooling resources and expertise, the Blueprint identifies cross-cutting areas of research, and confronts challenges too large for any single Institute or Center. The Blueprint makes collaboration a day-to-day part of how the NIH does business in neuroscience, complementing the basic missions of Blueprint partners. During each fiscal year, the partners contribute a small percentage of their funds to a common pool. Since the Blueprint's inception in 2004, this pool has comprised less than 1 percent of the total neuroscience research budget of the partners. In 2009, the Blueprint Grand Challenges were launched to catalyze research with the potential to transform our basic understanding of the brain and our approaches to treating brain disorders. * The Human Connectome Project is an effort to map the connections within the healthy brain. It is expected to help answer questions about how genes influence brain connectivity, and how this in turn relates to mood, personality and behavior. The investigators will collect brain imaging data, plus genetic and behavioral data from 1,200 adults. They are working to optimize brain imaging techniques to see the brain's wiring in unprecedented detail. * The Grand Challenge on Pain supports research to understand the changes in the nervous system that cause acute, temporary pain to become chronic. The initiative is supporting multi-investigator projects to partner researchers in the pain field with researchers in the neuroplasticity field. * The Blueprint Neurotherapeutics Network is helping small labs develop new drugs for nervous system disorders. The Network provides research funding, plus access to millions of dollars worth of services and expertise to assist in every step of the drug development process, from laboratory studies to preparation for clinical trials. Project teams across the U.S. have received funding to pursue drugs for conditions from vision loss to neurodegenerative disease to depression. Since its inception in 2004, the Blueprint has supported the development of new resources, tools and opportunities for neuroscientists. For example, the Blueprint supports several training programs to help students pursue interdisciplinary areas of neuroscience, and to bring students from underrepresented groups into the neurosciences. The Blueprint also funds efforts to develop new approaches to teaching neuroscience through K-12 instruction, museum exhibits and web-based platforms. From fiscal years 2007 to 2009, the Blueprint focused on three major themes of neuroscience - neurodegeneration, neurodevelopment, and neuroplasticity. These efforts enabled unique funding opportunities and training programs, and helped establish new resources including the Blueprint Non-Human Primate Brain Atlas.
Proper citation: NIH Blueprint for Neuroscience Research (RRID:SCR_003670) Copy
http://c-path.org/programs/pkd/
Consortium to develop evidence supporting the use of imaging Total Kidney Volume (TKV) as a prognostic biomarker that predicts the progression of Autosomal Dominant Polycystic Kidney Disease (ADPKD) to select patients likely to respond to therapy into clinical trials. It aims to replace the currently used measurement of glomerular filtration rate (GFR). Scientists will use the data collected to develop a disease progression model that will evaluate the relationship between TKV and the known complications of ADPKD, including rate of loss of kidney function, hypertension, gross hematuria, kidney stones, urinary tract infections, development of end-stage renal disease, and mortality. These analyses will be used to support the regulatory qualification of TKV as an accepted measure for assessing the progression of ADPKD in clinical trials in which new therapies are tested. PKDOC has the following goals: # Develop standard clinical data elements and definitions that are specific to ADPKD # Create a database of aggregated data from existing multiple, longitudinal, and well-characterized research registries maintained over decades by the leading institutions in ADPKD clinical investigation # Advance and harmonize the missions of regulatory agencies by creating tools that help with the evaluation of new pharmaceutical compounds # Develop a quantitative disease progression model to examine the linkage between TKV and disease outcomes
Proper citation: Polycystic Kidney Disease Outcomes Consortium (RRID:SCR_003674) Copy
Urinary kidney biomarkers (KIM-1, albumin, total protein, 2-microglobulin, cystatin C, clusterin and trefoil factor-3) that are considered acceptable biomarkers for the detection of acute drug-induced nephrotoxicity in rats and can be included along with traditional clinical chemistry markers and histopathology in toxicology studies. These biomarkers may be used voluntarily as additional evidence of nephrotoxicity in nonclinical safety assessment studies to complement the standard data (BUN and sCr). In ROC analyses, some of these biomarkers showed better sensitivity and specificity than BUN and sCr relative to histopathological alterations considered to be the gold standard when tested with a limited number of nephrotoxicant and control compounds.
Proper citation: PSTC Nephrotoxicity Biomarkers (RRID:SCR_003709) Copy
Private research university located in the Boston suburb of Waltham, Massachusetts. Founded in 1948 as a non-sectarian, coeducational institution sponsored by the Jewish community, Brandeis was established on the site of the former Middlesex University.
Proper citation: Brandeis University; Massachusetts; USA (RRID:SCR_003669) Copy
A collaborative network among university-led drug discovery centers and programs to allow scientists to exchange technical expertise on drug discovery and development strategies as well as form partnerships with each other, biopharma companies, and drug discovery-focused contract service organizations and consultants. The website will also serve as a repository for drug discovery events, educational material, job postings, and partnership opportunities. Through active member participation this website will become a valuable tool for every scientist working in the drug discovery arena. In addition, involvement of members will enable them to effectively advocate to the NIH and other funding agencies to increase the awareness of the growing number of academic drug discovery scientists and their success as well as their needs.
Proper citation: Academic Drug Discovery Consortium (RRID:SCR_003706) Copy
Can't find your Tool?
We recommend that you click next to the search bar to check some helpful tips on searches and refine your search firstly. Alternatively, please register your tool with the SciCrunch Registry by adding a little information to a web form, logging in will enable users to create a provisional RRID, but it not required to submit.
Welcome to the nidm-terms Resources search. From here you can search through a compilation of resources used by nidm-terms and see how data is organized within our community.
You are currently on the Community Resources tab looking through categories and sources that nidm-terms has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.
If you have an account on nidm-terms then you can log in from here to get additional features in nidm-terms such as Collections, Saved Searches, and managing Resources.
Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:
You can save any searches you perform for quick access to later from here.
We recognized your search term and included synonyms and inferred terms along side your term to help get the data you are looking for.
If you are logged into nidm-terms you can add data records to your collections to create custom spreadsheets across multiple sources of data.
Here are the sources that were queried against in your search that you can investigate further.
Here are the categories present within nidm-terms that you can filter your data on
Here are the subcategories present within this category that you can filter your data on
If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.
